The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group
Purpose of Review
The aim of this report is to summarize the conclusions of the II Regional Meeting on Histoplasmosis in the Americas held in Manaus, Brazil, on March 22–24, 2019.
Persons living with advanced HIV are at high risk for developing histoplasmosis. Clinical signs and symptoms of this disease are often non-specific, making it difficult to establish a diagnosis. Although with the recent technological advances, in vitro diagnostics and medicines for histoplasmosis are often not available in many regions around the world. In addition, histoplasmosis is often not included in HIV care and treatment programs, resulting in inadequate health system planning and missed opportunities to save lives.
The II Regional Meeting on Histoplasmosis in the Americas gathered a multidisciplinary audience. Developed recommendations to be included in the WHO guidelines for diagnosis and treatment of histoplasmosis in advanced HIV were the product of this meeting, and guidelines are aimed to be published in early 2020.
KeywordsHistoplasma Histoplasmosis Diagnosis Treatment Guidelines AIDS
We want to thank all the International Histoplasmosis Advocacy Group (iHAG) members: https://docs.google.com/spreadsheets/d/189W6gMfVb2zW5StAW2U2AbwVwGhls8bkAc7npZgNdC8/edit?ts=5d6d4758#gid=474498568. We also want to thank Eduardo Serrão for the meeting logistics and Pooja Gandhi for editing the manuscript. iHAG 2019 co-sponsors: Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Instituto Nacional de Pesquisas da Amazôna (INPA), Global Action Fund for Fungal Infections (GAFFI), International Society for Human and Animal Mycology (ISHAM), Mycoses Study Group Education and Research Consortium (MSGERC), Centre d'Investigation Clinique INSERM, Centre Hospitalier de Cayenne, Universidad del Rosario, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), and Santa Casa de Misericórdia de Porto Alegre.
Compliance with Ethical Standards
Conflict of Interest
The findings and the conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Caceres DH, Knuth M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi (Basel). 2019;5(3). https://doi.org/10.3390/jof5030076Systematic review and meta-analysis on diagnostics assays for histoplasmosis in people living with HIV. CrossRefGoogle Scholar
- 5.• Nacher M, Blanchet D, Bongomin F, Chakrabarti A, Couppié P, Demar M, et al. Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: a systematic review of diagnostic accuracy studies. PLoS neglected tropical diseases. 2018;12(10):e0006802. https://doi.org/10.1371/journal.pntd.0006802Systematic review onHistoplasmaantigen testing performance. CrossRefPubMedPubMedCentralGoogle Scholar
- 6.•• WHO. Second WHO Model List of Essential In Vitro Diagnostics 2019 [Available from: https://www.who.int/medical_devices/publications/Standalone_document_v8.pdf?ua=1. World Health Organization second model list of essential in vitro diagnostics.
- 7.• Mathieu N, Antoine A. Proceedings of First Histoplasmosis in the Americas and the Caribbean Meeting, Paramaribo, Suriname, December 4–6, 2015. Emerging Infectious Disease journal. 2016;22(9). https://doi.org/10.3201/eid2209.160408Summary of the first histoplasmosis in the Americas meeting.